HanchorBio

Clinical stage Immunotherapy company’s Fc-Based Designer Biologics (FBDB™) platform is designed to engineer ligand traps to synergistically block multi-ligand interactions required for adaptive and innate immune activation. The company’s pipeline includes many additional engineered drug candidates with superior preclinical tumor cell killing and growth inhibition.